DYD Establishing U.S. Branch with Support from Maryland State Government

DYD announced on April 22 that it is in the process of establishing a local branch in the United States through a soft-landing support program offered by a U.S. state government. This initiative is part of a strategy to jointly target the U.S. market in partnership with MIJ, which is supported by Gangwon Special Self-Governing Province.

The establishment of the U.S. branch is based on a soft-landing memorandum of understanding (MOU) signed in March with Montgomery County. The soft-landing program is designed to support promising foreign companies entering the U.S. market. Subsequently, upon recommendation from Montgomery County, DYD signed an additional MOU with a U.S. clinical contract organization (CLIA Lab).

Through the CLIA Lab, DYD can utilize its proprietary laboratory-developed test (LDT) without separate FDA (Food and Drug Administration) approval, saving both time and costs. Montgomery County is home to both the FDA and the NIH (National Institutes of Health), providing favorable conditions for attracting investment from bio companies.

Building on this entry into the U.S. market, DYD will begin conducting clinical trials and implementing its full-scale business strategy in the United States. In February, the company established a public-private cooperation system for the advancement of the semiconductor industry together with Gangwon Special Self-Governing Province and medical device manufacturer MIJ. Gangwon Special Self-Governing Province is actively working to foster the bio industry ecosystem and advance semiconductor technology.

DYD is preparing to build a production base for mass production of bio-semiconductor technology and a saliva-based glycated albumin diagnostic kit in collaboration with these partners. The diagnostic kit requires only one minute for measurement and, since it is based on a semiconductor wafer, does not require an amplification process, making it highly cost-effective. Product optimization has been completed, and the company plans to begin mass production and exports following FDA approval in the future.

DYD stated, "During the visit of the Governor of Maryland to Korea from April 16 to 19, preliminary meetings and detailed discussions were held regarding cooperation in the bio industry with Gangwon Province," adding, "We expect that the collaboration between the two local governments will serve as a catalyst for DYD and MIJ to successfully enter the U.S. market."